U.S. Wireless Telecom Stock News

J.B. Hunt Transport Services (JBHT) is back in the spotlight after the Federal Reserve’s rate cut, with several high profile commentators pointing to the shipper as a prime beneficiary of easing financial conditions. See our latest analysis for J.B. Hunt Transport Services. That optimism is already showing up in the numbers, with the stock delivering a powerful 22.03 percent 1 month share price return and a 45.71 percent 3 month share price return. Longer term total shareholder returns look...

Morgan Stanley's upbeat wafer fab equipment outlook, supported by demand from TSMC and DRAM, has put KLA (KLAC) back in focus. Strong cash flows and bullish options activity are prompting investors to reassess the stock's potential upside. See our latest analysis for KLA. Despite a sharp 1 day share price pullback, KLA still sits near its record high at $1,193.92, with a 30 day share price return of 5.25 percent, a 90 day share price return of 20.73 percent and a standout year to date share...

Delek US Holdings (DK) has been on a volatile run lately, with the share price sliding over the past month despite a strong year to date. That disconnect has value focused investors paying closer attention. See our latest analysis for Delek US Holdings. Despite that recent pullback, the bigger picture remains impressive, with an 85.47% year to date share price return and a 106.38% one year total shareholder return. This suggests strong but cooling momentum as investors reassess risk and...

Royalty Pharma (RPRX) is back in focus after TD Cowen reaffirmed its buy rating and lifted expectations, adding to a string of upbeat calls from other major firms that are steadily reshaping sentiment. See our latest analysis for Royalty Pharma. Despite a softer patch in the last week, with a negative 7 day share price return, Royalty Pharma’s roughly 49 percent year to date share price return and 58 percent one year total shareholder return show that momentum is still firmly building behind...

Darling Ingredients (DAR) has quietly put together a solid stretch of returns, with the stock up about 5% over the past month and roughly 17% in the past 3 months. See our latest analysis for Darling Ingredients. That recent 16.6% 3 month share price return looks more like a recovery bounce than a breakout, especially when you set it against a flat 1 year total shareholder return and weak longer term figures. If Darling Ingredients has you rethinking where the next leg of growth might come...

Following SLM Corp.’s recent Investor Forum, several analysts adjusted their views, highlighting concerns over lower gain-on-sale margins from loan sales and higher operating expenses, while the company remains profitable. The split between cautious downgrades and ongoing positive ratings underscores how the same guidance update is being interpreted in very different ways by the analyst community. We’ll now examine how these revised expectations for gain-on-sale margins and expenses may...

If you are wondering whether Microsoft is still worth considering after its strong run over the last few years, or if most of the potential upside is already priced in, this article is for you. Despite a strong longer term track record, with the share price up 100.2% over 3 years and 128.1% over 5 years, the stock has cooled recently, slipping 1.0% over the past week and 6.2% over the last month. It still sits 14.3% higher year to date and 7.8% above where it was a year ago. Recent headlines...

Arrowhead Pharmaceuticals (ARWR) has had a busy stretch, with REDEMPLO winning FDA approval, plozasiran earning Breakthrough Therapy status, and ARO MAPT entering human trials, all of which are reshaping how investors view the stock. See our latest analysis for Arrowhead Pharmaceuticals. All of this clinical and regulatory momentum has shown up in the numbers, with a roughly 70 percent 1 month share price return and a powerful 220 percent 1 year total shareholder return. This suggests...

Omnicell (OMCL) just rolled out Titan XT, an enterprise grade automated dispensing platform tightly integrated with its OmniSphere cloud, and investors are already asking what this means for growth and the stock. See our latest analysis for Omnicell. The launch of Titan XT lands after a strong run in the shares, with a 30 day share price return of roughly 25 percent and a 90 day gain of about 36 percent. This comes even though the 1 year total shareholder return remains slightly negative,...

FDA acceptance of ReadyFlow Autoinjector sNDA puts MannKind in focus MannKind (MNKD) just got a meaningful catalyst: the FDA accepted its supplemental new drug application for the FUROSCIX ReadyFlow Autoinjector, setting a July 26, 2026 action date that investors will now anchor on. See our latest analysis for MannKind. The ReadyFlow sNDA news has added a clear spark to sentiment, with a 1 month share price return of 17.39 percent lifting MannKind to 5.94 dollars even though year to date...

Planet Labs PBC (PL) just delivered a quarter that checked several important boxes for investors, with faster revenue growth, four straight quarters of adjusted EBITDA profit, and a guidance hike for fiscal 2026. See our latest analysis for Planet Labs PBC. The market has been quick to reward that progress, with the stock now at $18.24 and a blistering year to date share price return of 359.45 percent. The 1 year total shareholder return of 354.86 percent and 3 year total shareholder return...

Spire (SR) has quietly put together a solid run this year, with the stock up about 22% year to date and nearly 28% over the past year, easily outpacing many utilities peers. See our latest analysis for Spire. The latest move to around $83 per share builds on steady buying over recent months, with a 90 day share price return of about 9 percent and a one year total shareholder return above 28 percent. This suggests positive momentum rather than a speculative spike. If Spire’s run has you...

Arcus Biosciences, Inc., has drawn fresh attention after scrapping its late stage STAR-221 and EDGE-Gastric trials in upper gastrointestinal cancers, a setback that also clarifies where the next wave of potential value may come from. See our latest analysis for Arcus Biosciences. The abrupt end to STAR-221 and EDGE-Gastric triggered a sharp reset in sentiment, with a 1 day share price return of minus 14.36 percent. Arcus still posts an 85.92 percent 3 month share price return and a 33.89...

Brinker International (EAT) grabbed attention after upbeat reports from JPMorgan and Citigroup, as both firms pointed to effective cost cuts and stronger guest traffic as key drivers of renewed investor confidence. See our latest analysis for Brinker International. The upbeat commentary from JPMorgan and Citigroup lands at a time when momentum is clearly building, with a 1 month share price return of 27.62 percent helping push Brinker to $144.45 and supporting a 3 year total shareholder...

If you are wondering whether Ascendis Pharma at around $220 a share is still good value after such a strong run, you are not alone. That is exactly what this breakdown is going to tackle. The stock has climbed 7.3% over the last week, 7.8% over the past month, and is up 59.7% year to date and 69.7% over the last year, signaling that market expectations and risk perceptions have shifted meaningfully. Recent headlines have focused on Ascendis progress in advancing and de-risking its...

In recent days, PTC announced that HOLON, a BENTELER Group subsidiary, is using its Windchill+ SaaS PLM platform to develop an autonomous Level-4 electric vehicle and also launched its Arena AI Engine to automate document review, comparison, and compliance in PLM and QMS workflows. Together, these moves highlight PTC’s push to embed AI into cloud-based product lifecycle tools that underpin complex, highly regulated manufacturing projects like autonomous EVs. We’ll now examine how PTC’s...

Earlier in December 2025, law firm Hagens Berman began investigating Alvotech after the FDA issued a Complete Response Letter citing deficiencies at its Reykjavik manufacturing facility, prompting the company to sharply reduce its 2025 revenue and adjusted EBITDA guidance for its lead biosimilar candidate AVT05. This combination of regulatory setbacks and questions over prior disclosures highlights how central manufacturing quality and transparent guidance are to Alvotech’s biosimilar-led...

In December 2025, ADP, Inc. integrated Thatch’s Individual Coverage Health Reimbursement Arrangement platform into its RUN Powered by ADP payroll system and launched the Save4Retirement Pooled Employer Plan, embedding health and retirement benefits directly into payroll workflows for small and mid-sized employers. Together, these moves highlight how ADP is deepening its role as a core infrastructure provider for outsourced HR, linking payroll with healthcare and retirement administration to...

In October 2025, Genuine Parts Company reported third-quarter sales rising 4.9% year over year, supported by comparable sales growth and acquisitions across its global automotive and industrial parts network. The company also raised its full-year 2025 revenue growth outlook to 3–4%, signaling management’s confidence in execution despite a challenging macroeconomic backdrop. We’ll now explore how Genuine Parts’ upgraded full-year revenue outlook could shape its existing investment narrative...

Recently, Citizens reiterated its Market Outperform rating on Global-E Online, underscoring the company’s leadership in cross-border e-commerce and its strong relationship with Shopify as key strengths supporting its long-term business outlook. The report also highlighted Global-E’s healthy financial position and expanding merchant pipeline, suggesting that its role in a growing cross-border e-commerce market could reinforce confidence in its future earnings potential. Now, we’ll explore how...

FIGS recently reported third-quarter 2025 results that exceeded market expectations for both earnings per share and revenue, underscoring solid operating execution in its healthcare apparel business. Analysts have since highlighted FIGS' international expansion and upcoming Winter Olympics-linked marketing campaigns as potentially meaningful growth drivers for its direct-to-consumer model. We’ll now explore how FIGS’ stronger-than-expected quarterly performance could influence its existing...

TriNet Group, Inc. recently announced that its Board of Directors approved a quarterly cash dividend of US$0.275 per share, with a record and ex-dividend date of January 2, 2026 and a payout date of January 26, 2026. This cash dividend underscores TriNet's ongoing emphasis on returning cash to shareholders, which may be an important signal about capital allocation priorities. We’ll examine how this newly declared US$0.275 per-share dividend influences TriNet’s investment narrative around...

Earlier this month, Redwire Corporation presented at the 14th Annual ROTH Deer Valley Event, highlighting its $44 million DARPA Otter VLEO mission contract, the integration of Edge Autonomy, and recent facility expansion in Michigan. Investor attention is also being drawn to Redwire’s potential role in emerging space-based data center projects alongside existing partners Blue Origin and SpaceX, which could broaden its foothold in next-generation space infrastructure. Now we’ll examine how...

MoonLake Immunotherapeutics (MLTX) is back in the spotlight after disclosing that lead drug candidate sonelokimab fell short of a rival treatment in Phase 3 trials, triggering lawsuits and a brutal repricing of the stock. See our latest analysis for MoonLake Immunotherapeutics. The latest bounce to a share price of $14.79, reflected in a 1 month share price return of 15.82 percent, comes after a brutal 90 day share price collapse of 72.24 percent and a 1 year total shareholder return of...